A recent DGIST study shows somatostatin overexpression reduces inflammation and amyloid β in mice, suggesting repurposing existing drugs like octreotide could accelerate Alzheimer’s therapy and...
Recent studies highlight how probiotics and fecal microbiota transplantation reduce neuroinflammation and improve cognitive function in neurodegenerative diseases, offering new treatment avenues. New ...
Recent research shows probiotics and fecal microbiota transplantation reduce neuroinflammation via the gut-brain axis, offering promising therapies for neurodegenerative diseases with clinical trials ...
Exploring recent advances in senolytic and senomorphic therapies, including dasatinib-quercetin and immune-based approaches, to combat age-related diseases like Alzheimer’s and sarcopenia. New t...
Recent research shows lipid nanoparticles delivering mRNA can reduce tau protein aggregates in Alzheimer’s models, with Moderna advancing clinical trials and regulatory support accelerating deve...
Recent studies reveal aging microglia can promote amyloid-β aggregation, shifting Alzheimer’s pathology understanding and highlighting new therapeutic strategies targeting immune-brain interact...
The cGAS-STING pathway, crucial for innate immunity, drives harmful neuroinflammation in aging and Alzheimer’s, with recent studies highlighting therapeutic challenges and biomarker potential fo...
A July 2024 study in ‘Nature Aging’ validates p-tau217 blood biomarkers for forecasting Alzheimer’s symptoms within 3-4 years, enhancing early intervention and personalized medicine....
Recent studies validate blood biomarkers like p-tau217 for predicting Alzheimer’s onset within 3-4 years at 94% accuracy, enabling early interventions but raising ethical and socioeconomic conce...
A new blood test based on p-tau217 biomarker can predict Alzheimer’s symptom onset in 3-4 years with high accuracy, offering early intervention opportunities. Recent studies validate a p-tau217 ...
